PT - JOURNAL ARTICLE AU - Justin D. Salciccioli AU - Dominic C. Marshall AU - Richard Goodall AU - Conor Crowley AU - Joseph Shalhoub AU - Preya Patel AU - Philip L. Molyneaux TI - Interstitial lung disease incidence and mortality in the United Kingdom and the European Union: an observational study, 2001–2017 AID - 10.1183/23120541.00058-2022 DP - 2022 Jan 01 TA - ERJ Open Research PG - 00058-2022 4099 - http://openres.ersjournals.com/content/early/2022/04/07/23120541.00058-2022.short 4100 - http://openres.ersjournals.com/content/early/2022/04/07/23120541.00058-2022.full AB - Objective To compare the trends in age-standardised incidence and mortality from interstitial lung diseases (ILD) in the United Kingdom (UK) and the European Union (EU).Design Observational study using data obtained from the Global Burden of Disease Study.Setting and Participants Residents of the UK and of the twenty-seven EU countries.Main outcome measures ILD age-standardised incidence rates per 100 000 (ASIR), age-standardised death rates per 100 000 (ASDR), and mortality-to-incidence ratio (MIRs) are presented for males and females separately for each country, for the years 2001–2017. Trends were analysed using Joinpoint regression analysis.Results For men, in 2017, the median incidence of ILD was 7.22 (IQR 5.57–8.96) per 100 000 population. For women, in 2017, the median incidence of ILD was 4.34 (IQR 3.36–6.29) per 100 000 population. For men, in 2017, the median ASDR attributed to ILD was 2.04 (IQR 1.13–2.71) per 100 000 population. For women, the median ASDR in 2017 for ILD was 1.02 (0.68–1.37) per 100 000 population. There was an overall increase in ASDR during the observation period with a median change of +20.42% (IQR 5.44–31.40) for men and an increase of +15.44% (IQR −1.01–31.52) for women. Despite increases in mortality over the entire observation period, there were decreasing mortality trends in the majority of countries at the end of the observation period (75% for men and 86% for women).Conclusion Over the past two decades, there have been increases in the incidence and mortality of interstitial lung diseases in Europe. The most recent trends, however, demonstrate decreases in mortality from ILD in the majority of European countries for both men and women. These data support the ongoing improvements in the diagnosis and management of ILD.FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflict of interest: Dr. Salciccioli has nothing to disclose.Conflict of interest: Dr. Marshall has nothing to disclose.Conflict of interest: Dr. Goodall has nothing to disclose.Conflict of interest: Conor Crowley has nothing to disclose.Conflict of interest: Dr. Shalhoub reports grants from UK National Institute for Health Research, outside the submitted work.Conflict of interest:Conflict of interest: Dr. Molyneaux, via his institution received industry-academic funding from AstraZeneca and has received speaker and consultancy fees from Boehringer Ingelheim and Hoffman-La Roche outside the submitted work.